Nancy Holekamp, MD

Genentech announced the FDA has approved ranibizumab 100 mg/mL injection for wet age-related macular degeneration in patients who previously responded to at least two anti-VEGF injections.

In a video interview, Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, talked about suprachoroidal delivery of Regenxbio’s gene therapy RGX-314 for neovascular age-related macular degeneration.

Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, discussed results from the ARCHWAY phase 3 trial of the Port Delivery System with ranibizumab presented at the ASRS annual meeting.

In a Healio video interview, Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, discussed her ASRS presentation on ANX007, a novel C1q inhibitor for advanced dry age-related macular degeneration.

Genentech announced the FDA has approved ranibizumab 100 mg/mL injection for wet age-related macular degeneration in patients who previously responded to at least two anti-VEGF injections.

VANCOUVER, British Columbia ― Nancy Holekamp, MD, discusses two studies she presented here at the American Society of Retina Specialists meeting showing the effectiveness of the Iluvien implant (fluocinolone acetonide, Alimera Sciences) in the treatment of diabetic macular edema.